Filer Snapshot

Amy Schacterle

CIK 0002042021. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity Type

Individual

Total Filings

6

Latest Filing

21 Jan 2026

Industry

n/a

Follow future filing-backed changes

Save this filer to return when a new filing changes the portfolio, large-stake, insider, or company context.

Save and revisit

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Best next click

Start with the summary below, then verify the strongest source-backed page for this filer.

  • Open 13F if you want portfolio holdings.
  • Open 13D/G or insider pages only when this CIK has those rows.
Source: SEC Forms 3/4/5

4 filed on 21 Jan 2026 for CIK 0002042021.

View Source Filing
Business address
C/O Acumen Pharmaceuticals, Inc., 1210 1220 Washington Street, Suite 210, Newton, MA, 02465
Top holdings (ownership)
ABOS

Filer intelligence

What SEC filings say about Amy Schacterle

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Quick read

  • Forms 3/4/5 show insider context for ABOS worth $194.7K.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

Forms 3/4/5 insider context

ABOS

16 Jan 2026 ยท Chief Regulatory Officer

$194.7K

Latest update

What changed recently for Amy Schacterle

Ownership report updated

Latest ownership report period: 16 Jan 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

21 Jan 2026

Page type

Ownership filings

Latest period

16 Jan 2026

Ownership context was refreshed from SEC Forms 3/4/5 filed on 21 Jan 2026.

Filer Overview

Amy Schacterle has filed 6 SEC EDGAR filings since 06 Nov 2024. Common forms include 4, 144, 3.

Latest Filings

Recent SEC filings for Amy Schacterle with direct links to document and filing folders.

4 File 001-40551

FORM 4

Filing date
21 Jan 2026
Reporting date
16 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-40551

FORM 4

Filing date
09 Jan 2026
Reporting date
07 Jan 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
144

144 filing

Filing date
07 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-40551

FORM 4

Filing date
07 Jan 2025
Reporting date
06 Jan 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-40551

4

Filing date
06 Nov 2024
Reporting date
05 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
3 File 001-40551

3

Filing date
06 Nov 2024
Reporting date
05 Nov 2024
SEC evidence
Open document Open filing
Next action
Verify source filing

About this filer

Amy Schacterle files with the SEC under CIK 0002042021. This page aggregates EDGAR filings and related ownership activity.

FAQ

What is a CIK?
A Central Index Key (CIK) is a unique identifier assigned by the SEC to each filer.
Why are some filings missing?
New filings appear as the SEC updates EDGAR, and older records can vary by availability.
How often is this page updated?
Updates follow new EDGAR submissions and periodic data refreshes.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .